Latest news
30.09.2021
DEINOVE presents its financial results and the advancement of its programs for the first half of 2021
Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected in Q4 2021 Strengthening of...
22.09.2021
Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on September 13, 2021
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
14.09.2021
Implementation of an agreement of notes convertible into new shares for a maximum nominal amount of €10M. Issuance of a first €500,000 tranche
This new agreement with European Select Growth Opportunities Fund enables the issuance of notes convertible into new shares for a maximum...
Press Coverage
09.03.2021
La Gazette de Montpellier - Live - Le projet Boost ID de la biotech montpelliéraine DEINOVE
12.05.2020
Cdiff Foundation | A New Parenteral Treatment for a Severe C. difficile Infection
"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla Join us with our two guests: Dr Yannick Pletan...
08.05.2020
Biotech & Finance | Alexis Rideau, arrive chez Deinove avec son réseau industriel et académique de pointe
C’est une nouvelle aventure pour Alexis Rideau, qui occupe depuis cette semaine la fonction de directeur général délégué de Deinove...